Eli Lilly and Co. completed the first phase of a $560 million expansion to its biotech complex in Indianapolis. The investment is part of a $1 billion effort to strengthen and build its biotech drug R&D capabilities. Lilly’s plans for the complex, announced in 2002, have since doubled in size to meet its pipeline of biopharma drugs. Approximately 30% of Lilly’s total drug portfolio are biopharma medicines in several therapeutic categories. With the state-of-the-art bioprodu...